Breaking News, Collaborations & Alliances

Crown Bio, Charles River Enter Discovery Agreement

Enables greater global model availability for drug discovery in obesity, diabetes and metabolic syndrome

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research has entered a licensing agreement with Charles River Laboratories’s research models and services business.   The agreement, designed to expand access to CrownBio’s ZDSD (Zucker Diabetic Sprague-Dawley) rat provides Charles River, a leader in research model distribution, an exclusive license to breed and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters